Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn

thetimes.com

Alex Ralph (thetimes.com)

Company was spun out of the Beckley Foundation which has its origins in an aristocrat’s Tudor hunting lodge

A psychedelic drugs company whose lead asset is based on a chemical found in the Sonoran Desert toad, and whose origins lie with an Oxfordshire aristocrat, has been acquired by Eli Lilly for up to $3.8 billion.

AtaiBeckley, listed on New York’s Nasdaq, has agreed a sale to the US pharma group a few months after the market was lifted by President Trump’s executive order directing regulators to speed up reviews of psychedelic therapies and to increase federal research funding.

The company was created a year ago through the $390 million all-share combination between Atai Life Sciences and Beckley Psytech. The latter was spun out of the Beckley Foundation, an institute founded in 1998 to research the effects of psychoactive drugs that was started by the late Amanda Feilding, the Countess of Wemyss and March. It was registered at Beckley Park, the family home, a Tudor hunting lodge near Oxford.

Cosmo Feilding Mellen, 41, her son, who was chief executive of Beckley Psytech, remained a shareholder in AtaiBeckley following last year’s combination, holding a stake of about 2 per cent, according to FactSet data. Lilly’s takeover values his stake at more than $50 million.

Early investors in Beckley Psytech, which was incorporated in 2018, included Jim Mellon, the businessman and investor, and Richard Reed, a co-founder of Innocent Drinks.

Original Article

Tolemy Bio lands €1.4M to power AI-driven cell biology

tech.eu

Tamara Djurickovic (tech.eu)

With new funding, Tolemy Bio plans to advance its AI-enabled cell biology platform designed to help biopharma teams better interpret, optimise, and manage experimental research workflows.

Cambridge-based biotech startup Tolemy Bio has raised €1.4 million in pre-seed funding to advance its AI-enabled technology for cell biology research and biopharma development. The round was led by Norrsken Evolve, with participation from Big Sur Ventures, JME Ventures, Masia, and a new UK-based stealth fund.

Founded by Alex Ward and Caelan Anderson, Tolemy Bio is developing Orbit, a system designed to help researchers better understand, interpret, and optimise living cells used in modern therapies and drug development.

The company is focused on a longstanding challenge within biopharma and cell biology: while living cells are central to areas such as cell therapies and therapeutic proteins, experimental workflows remain highly manual and fragmented.

Research data is often spread across spreadsheets, lab equipment, notebooks, and disconnected systems, limiting the ability of teams to effectively apply AI tools to drug development and manufacturing processes.

Orbit is designed to bring these fragmented workflows into a single AI-native environment. The system connects existing laboratory tools and experimental data sources, while also incorporating virtual cell models and AI research agents intended to help scientists analyse cellular behaviour and guide experimental decision-making.

Alex Ward, co-founder and CEO of Tolemy Bio, said the company was founded to address the difficulties researchers face in interpreting and reproducing complex cell biology experiments.

Our platform, Orbit, is designed to connect experimental data with AI models,” said Ward. “Our goal is to make complex cell biology easier to interpret, optimise, and apply to real therapeutic development.

The newly raised funding will be used to expand Tolemy Bio’s data generation, machine learning, and engineering capabilities, continue development of Orbit, and support early customer and partner deployments. While headquartered in Cambridge, the company says much of its operational activity will continue from Barcelona.

Tolemy Bio’s long-term goal is to build a virtual-cell platform that helps biopharma companies move beyond trial-and-error experimentation towards more precise and data-driven approaches to understanding and controlling living cells.

Original Article